{"id":"ao-128","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Liver enzyme elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting aldose reductase, AO-128 reduces the accumulation of sorbitol in tissues, which is thought to contribute to diabetic complications such as neuropathy, retinopathy, and nephropathy. This mechanism addresses the underlying metabolic dysfunction in diabetes-related microvascular complications.","oneSentence":"AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:26:21.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic peripheral neuropathy"},{"name":"Diabetic complications (retinopathy, nephropathy)"}]},"trialDetails":[{"nctId":"NCT01993927","phase":"","title":"Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance \"Long-term Use in Patients With Impaired Glucose Tolerance\"","status":"COMPLETED","sponsor":"Takeda","startDate":"2009-11-18","conditions":"Impaired Glucose Tolerance","enrollment":742},{"nctId":"NCT02287402","phase":"PHASE4","title":"Postmarketing Clinical Study on AO-128","status":"COMPLETED","sponsor":"Takeda","startDate":"2010-03","conditions":"Impaired Glucose Tolerance (IGT)","enrollment":197}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ATRIAL FIBRILLATION"},{"count":1,"reaction":"CEREBRAL INFARCTION"},{"count":1,"reaction":"VENTRICULAR EXTRASYSTOLES"}],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Voglibose","BASEN"],"phase":"marketed","status":"active","brandName":"AO-128","genericName":"AO-128","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AO-128 is a selective inhibitor of aldose reductase, an enzyme in the polyol pathway that converts glucose to sorbitol. Used for Diabetic peripheral neuropathy, Diabetic complications (retinopathy, nephropathy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}